Page 12 - ஜெஃப்பெரிஸ் மெய்நிகர் சுகாதாரம் மாநாடு News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Fate Therapeutics to Present at Upcoming Investor Conferences
yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.
Acacia Pharma to Participate in Jefferies Virtual Healthcare Conference
yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.
(0) ICON plc, (NASDAQ: ICLR) a global provider of outsourced drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device and government and public health organisations, today announced that Mr. Brendan Brennan, CFO of ICON plc, will present at the Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2021. The presentation will be webcast live from 08.00am ET. It was also announced that Dr. Steve Cutler, CEO of ICON plc, will present at the William Blair 41
st Growth Stock Conference on Wednesday, June 2, 2021. The presentation will be webcast live from 11.40am ET.
Any changes to these events and links to the live webcasts (where available) will be posted on the Investor section of our website under Events .
About Inventiva
Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of NASH, MPS and other diseases with significant unmet medical need.
Leveraging its expertise and experience in the domain of compounds targeting nuclear receptors, transcription factors and epigenetic modulation, Inventiva is currently advancing two clinical candidates, as well as a deep pipeline of earlier stage programs.
Lanifibranor, its lead product candidate, is being developed for the treatment of patients with NASH, a common and progressive chronic liver disease for which there are currently no approved therapies. In 2020, Inventiva announced positive topline data from its Phase IIb clinical trial evaluating lanifibranor for the treatment of patients with NASH and obtained Breakthrough Therapy and Fast Track designation for lanifibranor in the treatment of NASH.
West Announces Participation in Upcoming Investor Conference
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.